Bio-Path Holdings, Inc. (NASDAQ:BPTH) announced its earnings results on Thursday. The company reported ($0.03) earnings per share for the quarter, missing the consensus estimate of ($0.02) by $0.01, Bloomberg Earnings reports.
Shares of Bio-Path Holdings (BPTH) opened at 0.295 on Friday. The firm’s 50-day moving average price is $0.38 and its 200 day moving average price is $0.61. The company’s market cap is $29.52 million. Bio-Path Holdings has a 52 week low of $0.26 and a 52 week high of $1.72.
Large investors have recently added to or reduced their stakes in the company. Legal & General Group Plc raised its stake in Bio-Path Holdings by 5,474.3% in the second quarter. Legal & General Group Plc now owns 1,773,799 shares of the company’s stock worth $681,000 after buying an additional 1,741,978 shares during the period. Tower Research Capital LLC TRC acquired a new stake in Bio-Path Holdings during the first quarter worth approximately $105,000. HighTower Advisors LLC raised its stake in Bio-Path Holdings by 9.1% in the first quarter. HighTower Advisors LLC now owns 1,263,070 shares of the company’s stock worth $1,043,000 after buying an additional 105,000 shares during the period. Sabby Management LLC raised its stake in Bio-Path Holdings by 3.5% in the first quarter. Sabby Management LLC now owns 687,398 shares of the company’s stock worth $569,000 after buying an additional 23,352 shares during the period. Finally, Bank of New York Mellon Corp raised its stake in Bio-Path Holdings by 1.7% in the first quarter. Bank of New York Mellon Corp now owns 311,645 shares of the company’s stock worth $257,000 after buying an additional 5,172 shares during the period. Institutional investors and hedge funds own 19.90% of the company’s stock.
Several analysts have weighed in on BPTH shares. HC Wainwright reaffirmed a “buy” rating and set a $5.00 target price on shares of Bio-Path Holdings in a research note on Tuesday, July 4th. Zacks Investment Research downgraded Bio-Path Holdings from a “buy” rating to a “hold” rating in a research note on Wednesday, July 12th.
Bio-Path Holdings Company Profile
Bio-Path Holdings, Inc is a clinical and preclinical stage oncology focused antisense drug development company. The Company utilizes a technology that achieves systemic delivery for target specific protein inhibition for any gene product that is over-expressed in disease. Its drug delivery and antisense technology, DNAbilize, is a platform that uses P-ethoxy, a deoxyribonucleic acid backbone modification.
Receive News & Ratings for Bio-Path Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Path Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.